No insider purchase over the last 90 days. The latest, by 엑시엄자산운용, was filed 18 Jun 2026.
ADBiotech Co., Ltd.: what insiders have been doing
ADBiotech Co., Ltd. belongs to the Health Care sector. Filings by its managers are published through DART (FSS). Between 2 November 2025 and 2 November 2026, 9 insiders published 19 filings.
Open-market activity splits into 11 purchases and 5 sales; 7 insiders sit on the buying side and 5 insiders on the selling side. No amount is published for 16 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 4 major shareholders and 1 chief executive among the declarants.
For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 19 filings here. Since 2021, the database holds 18 purchases and 34 sales by insiders of the company.
The latest purchase dates back some time: it was published 144 days ago, on 18 June 2026. Filings reach the DART (FSS) feed a median of 7 days after the trade. That lag is the time during which only the insider knows about the trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Who traded when
BuySale+9 other insiders
Since the insiders bought
- -33.8%Entry ₩2,850 · Close 30 Oct 2026 ₩1,886
- -0.2%Entry ₩1,890 · Close 30 Oct 2026 ₩1,886
- -7.1%Entry ₩2,030 · Close 30 Oct 2026 ₩1,886
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- 278,241 sharesKRXDART:20260618000305Canonical exit: 16 Sept 2026 (T+90)
- 3,319,251 sharesKRXDART:20260611000377Canonical exit: 9 Sept 2026 (T+90)
- 2,668,523 sharesKRXDART:20260605000485Canonical exit: 3 Sept 2026 (T+90)
- 5,987,774 sharesShareKRXDART:20260605000499Canonical exit: 3 Sept 2026 (T+90)
- ●Executives0DART
- 113,493 sharesKRXDART:20260522000557
- ●Executives0DART
- 3,319,251 sharesKRXDART:20260410003530Canonical exit: 2 Jul 2026 (T+90)
- 1,050,276 sharesKRXDART:20260327001592
- ●Executives0DART
- 1,050,276 sharesKRXDART:20260227007650Canonical exit: 21 May 2026 (T+90)
- 174,603 sharesKRXDART:20260120000311Canonical exit: 30 Mar 2026 (T+90)
- 1,069,397 sharesShareKRXDART:20260120000316
- 3,319,251 sharesKRXDART:20260119000150Canonical exit: 14 Apr 2026 (T+90)
- 3,319,251 sharesShareKRXDART:20260119000154Canonical exit: 19 Apr 2026 (T+90)
- 2,281,580 sharesKRXDART:20260113000469
- 122,966 sharesKRXDART:20251229000565
- 1,000 sharesShareKRXDART:20251216000344Canonical exit: 16 Mar 2026 (T+90)
- 2,281,580 sharesKRXDART:20251202000159Canonical exit: 26 Feb 2026 (T+90)
- 170,000 sharesKRXDART:20251028000325Canonical exit: 22 Jan 2026 (T+90)
- 12,000 sharesShareKRXDART:20251028000387
- 104,166 sharesKRXDART:20251001000731
25 of 64 declarations
About ADBiotech Co., Ltd.
애드바이오텍 is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions for patient health and well-being.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
